For the quarter ended March 2025, Boston Scientific (BSX) reported revenue of $4.66 billion, up 20.9% over the same period last year. EPS came in at $0.75, compared to $0.56 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $4.56 billion, representing a surprise of +2.31%. The company delivered an EPS surprise of +11.94%, with the consensus EPS estimate being $0.67.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Boston Scientific performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Geographic Revenue- Rest of the World: $1.70 billion versus $1.70 billion estimated by three analysts on average.
- Geographic Revenue- U.S. $2.96 billion compared to the $2.86 billion average estimate based on three analysts. The reported number represents a change of +31.1% year over year.
- Net Sales- Cardiovascular- Peripheral Interventions- International: $280 million compared to the $290.75 million average estimate based on two analysts. The reported number represents a change of +2.2% year over year.
- Net Sales- MedSurg- Neuromodulation- United States: $204 million versus the two-analyst average estimate of $204.54 million. The reported number represents a year-over-year change of +7.4%.
- Net Sales- Cardiovascular- Worldwide: $3.09 billion compared to the $2.96 billion average estimate based on six analysts. The reported number represents a change of +26.2% year over year.
- Net Sales- MedSurg- Worldwide: $1.58 billion versus $1.59 billion estimated by six analysts on average. Compared to the year-ago quarter, this number represents a +11.7% change.
- Net Sales- MedSurg- Neuromodulation- Worldwide: $271 million versus the five-analyst average estimate of $266.87 million. The reported number represents a year-over-year change of +5.9%.
- Net Sales- Cardiovascular- Peripheral Interventions- Worldwide: $656 million compared to the $658.51 million average estimate based on five analysts. The reported number represents a change of +14.5% year over year.
- Net Sales- Cardiovascular- Cardiology- Worldwide: $2.43 billion versus $2.31 billion estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +29.8% change.
- Net Sales- MedSurg- Urology- Worldwide: $633 million versus $647.40 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +23.4% change.
- Net Sales- MedSurg- Endoscopy- Worldwide: $673 million versus the five-analyst average estimate of $675.07 million. The reported number represents a year-over-year change of +4.8%.
- Net Sales- Cardiovascular- Cardiac Rhythm Management (CRM)- Worldwide: $578 million compared to the $580.78 million average estimate based on four analysts. The reported number represents a change of +0.5% year over year.
View all Key Company Metrics for Boston Scientific here>>>
Shares of Boston Scientific have returned -7.8% over the past month versus the Zacks S&P 500 composite's -6.6% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Boston Scientific Corporation (BSX): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
